Advanced search×

Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.

Subha N Thiyagesh, Tom F D Farrow, Randolph W Parks, Hector Accosta-Mesa, Michael D Hunter, Claire Young, Iain D Wilkinson, and Peter W R Woodruff

Dement Geriatr Cogn Disord 29(2):176-88 (2010) PMID 20215749

Visuospatial impairments are known to occur in Alzheimer's disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing.

DOI: 275674
Version: za2963e q8za3 q8zb8 q8zc4 q8zd0 q8zea q8zf4 q8zg9

Similar articles you may find interesting…

  1. Endocannabinoids, FOXO and the metabolic syndrome: Redox, function and tipping point - The view from two systems
    Alistair VW Nunn, Geoffrey W Guy, and Jimmy D Bell

    Immunobiology 215(8):12 (2010) PMID 19457573

    We have proposed that the physiological and protective insulin resistance that underlies thriftiness encapsulates something called 'redox thriftiness', whereby insulin resistance is determined by the ability to resist oxidative stress. Modern man has removed most hormetic stimuli and replaced them w...
  2. Degenerative lumbar disc and facet disease in older adults: prevalence and clinical correlates.
    Gregory E GE Hicks, Natalia N Morone, and Debra K DK Weiner

    Spine (Phila Pa 1976) 34(12):1301-6 (2009) PMID 19455005

    Results demonstrated that the presence of degenerative disc and facet pathology in older adults is ubiquitous, regardless of clinical status, with greater than 90% demonstrating some level of degeneration. Higher radiographic severity scores were associated with the presence of CLBP. In fact, presen...
    View PDF
  3. A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in...
    Sofia Tzimopoulou, Vincent J Cunningham, ... Paul M Matthews

    J Alzheimers Dis (2010) PMID 20930300

    We report the first multi-center clinical trial in Alzheimer's disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARĪ³ agonist Rosiglitazone XR versus p...